株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界と中国のモノクローナル抗体産業:2019年~2025年

Global and China Monoclonal Antibody Industry Report, 2019-2025

発行 ResearchInChina 商品コード 261167
出版日 ページ情報 英文 180 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
世界と中国のモノクローナル抗体産業:2019年~2025年 Global and China Monoclonal Antibody Industry Report, 2019-2025
出版日: 2019年04月15日 ページ情報: 英文 180 Pages
概要

世界のモノクローナル抗体市場は、2018年の1,152億米ドルから、2025年には2,402億米ドルまで拡大すると予測されています。中国のモノクローナル抗体市場は、2018年の142億人民元から、2025年には1,207億人民元まで拡大すると予測されています。

当レポートでは、世界と中国のモノクローナル抗体産業について調査分析し、産業の概要、発展、市場の発展、主要企業などについて、体系的な情報を提供しています。

第1章 モノクローナル抗体産業の概要

  • 定義
  • 分類
  • 技術開発

第2章 世界のモノクローナル抗体産業の概要

  • 現状
  • 市場規模
  • 市場構造
  • 競合パターン
  • 発展見通しと予測

第3章 中国のモノクローナル抗体市場

  • 現状
  • 市場規模
  • 市場セグメント
  • 競合パターン
  • 発展見通し

第4章 世界の主なモノクローナル抗体エージェント企業

  • Roche Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co Inc.
  • Novartis
  • AbbVie
  • Amgen

第5章 中国の主なモノクローナル抗体エージェント企業

  • BIOTECH Pharmaceutical Co., Ltd.
  • Chengdu Taihe Health Technology Group Inc., Ltd.
  • Shanghai Medipharm Biotech Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Yunnan Walvax Biotechnology Co., Ltd.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Beijing SL Pharmaceutical Co., Ltd.
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Mabpharm Limited
  • Hualan Biological Engineering Inc.
  • Anhui Anke Biotechnology (Group) Co., Ltd.
  • Innovent Biologics, Inc.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Hengrui Medicine Co., Ltd.
  • Changchun High and New Technology Industries (Group) Inc.
  • Guilin Sanjin Pharmaceutical Co., Ltd.
  • Shenzhen Main Luck Pharmaceuticals Inc.
  • 3SBio Group
図表

Selected Charts

Composition of Monoclonal Antibodies Worldwide by Type, 2018

Targets of Some Monoclonal Antibodies Approved by FDA by May. 2018

Number of Global Approvals for Monoclonal Antibodies, 1986-2018

World's Top 10 Drugs by Sales, 2017

Sales Structure of Global Biological Drug Market (by Type), 2017

Keytruda Monoclonal Antibody Sales of Merck, 2014-2018

Global Monoclonal Antibody Market Size, 213-2025

Global Monoclonal Antibody Market Structure (by Therapeutic Field), 2017

Global Monoclonal Antibody Market Structure (by Therapeutic Field), 2018

Shares for Global Incidences with Cancer and Deaths, 2018

Shares for Incidence with Various Kinds of Cancer Worldwide, 2018

Shares for Male Incidence with Various Kinds of Cancer Worldwide, 2018

Shares for Female Incidence with Various Kinds of Cancer Worldwide, 2018

Shares for Incidences and Deaths by Regions Worldwide, 2018

Shares for Male Incidences and Deaths by Regions Worldwide, 2018

Shares for Female Incidences and Deaths by Regions Worldwide, 2018

Sales Revenue of Major Monoclonal Antibodies Worldwide, 2012-2018 (USD mln)

R&D Input of World-renowned Monoclonal Antibody Manufacturers, 2011-2018

Global Distribution of Clinical Research Phases for Monoclonal Antibody Drugs as of April 11, 2019

Expiry Dates for Major Monoclonal Antibodies Worldwide

PD-1/PD-L1 Targeted Monoclonal Antibody Drugs Approved by FDA as of October 2018

Mechanism of PD-1 Antibody

Immuno-Oncology PD-1 and PD-L1 Inhibitor Uptake in the United States

Opdivo and Keytruda Sales, 2014-2018

Global PD-1/PD-L1Monoclonal Antibody Market Size, 2014-2025E

Monoclonal Antibodies Approved for Marketing in China by April 2019

Some Monoclonal Antibody Products Covered by National and Regional Medical Insurance in China, by the end of 2018

R&D Progress of Main Monoclonal Antibody-like Biosimilars That Have Entered Phase III Clinical Trials in China, by H1 2018

Chinese Monoclonal Antibody Market Size, 2013-2025E

Cancer Incidence in China, 2013-2018

Price Comparison between Monoclonal Antibodies with and without Price Negotiations in China

Approval on Indications of Rituximab (FDA)

Rituximab R&D Progress in China, by Oct 2018

Chinese Rituximab Market Size, 2013-2025E

Chinese Bevacizumab Market Size, 2013-2025E

Bevacizumab R&D Progress in China, by Oct 2018

Chinese Trastuzumab Market Size, 2013-2025E

Trastuzumab Similimum R&D Progress in China, by H1 2018

Chinese Adalimumab Market Size, 2013-2025E

Adalimumab R&D Progress in China, by Oct 2018

Chinese Omalizumab Market Size, 2018-2025E

Chinese Cetuximab Market Size, 2013-2025E

Chinese Infliximab Market Size, 2013-2025E

R&D Progress of Main Monoclonal Antibody Companies in China

Year 2017 Availability of 55 Oncology Medicines First Launched Globally 2012-2016

Chinese PD-1/PDL-1Monoclonal Antibody Market Size, 2018-2025E

R&D Progress of Monoclonal Antibody Targeting PD-1 in China, by Oct 2018

R&D Progress of Monoclonal Antibody Targeting PD-L1 in China, by Oct 2018

Definitions of Biosimilars between China and Other International Organizations

Comparison between Duration of Biosimilar Patent Protection in China, Europe and America

Drug Registration Process in China and the United States

Major M&A Cases of Roche, 1990-2019

Roche's Global Presence

Revenue and Net Income of Roche, 2008-2018

Roche's Revenue (by Product), 2014-2018

Roche's Revenue (by Region), 2014-2018

R & D Costs of Roche (by Business), 2011-2018

Global Sales of Major Monoclonal Antibody Products of Roche (Genentech), 2010-2018

Roche's Mabthera/Rituxan Sales (by Region), 2011-2018

Roche's Avastin Sales (by Region), 2011-2018

Roche's Herceptin Sales (by Region), 2011-2018

Roche's Perjeta Sales (by Region), 2012-2018

Roche's Actemra/RoActemra Sales (by Region), 2011-2018

Roche's Kadcyla Sales (by Region), 2013-2018

Roche's Revenue in China (by Product), 2010-2018

Roche's Main Subsidiaries in China, 2018

Johnson & Johnson's Operating Results, 2010-2018

Johnson & Johnson's Revenue (by Division), 2009-2018

Sales of Johnson & Johnson's Main Pharmaceutical Products (by Region), 2013-2018

R&D Costs and % of Total Revenue of Johnson & Johnson, 2009-2018

Monoclonal Antibody Products of Johnson & Johnson

Monoclonal Antibody Sales of Johnson & Johnson, 2009-2018

Johnson & Johnson's Enterprises in China and Main Products

Merck's Operating Results, 2013-2018

Merck's Revenue (by Product), 2013-2018

Merck's Revenue (by Region), 2013-2018

R&D Costs and % of Total Revenue of Merck, 2009-2018

Merck's R&D Pipeline, as of Feb 22, 2019

Sales of Monoclonal Antibodies of Merck, 2011-2018

Merck's Revenue in China, 2016-2018

Revenue and Operating Income of Novartis, 2009-2018

Novartis' Revenue (by Division), 2015-2018

Novartis' Revenue Structure (by Division), 2015-2018

R&D Costs and % of Total Revenue of Novartis, 2009-2018

Novartis' Monoclonal Antibodies

Novartis' Monoclonal Antibody Revenue (by Product), 2013-2018

Novartis' Development Course in China

AbbVie's Operating Results, 2014-2018

Main Sales Regions and Indications of HUMIRA

AbbVie's Revenue (by Product), 2013-2018

AbbVie's Revenue (by Region), 2013-2018

R&D Costs and % of AbbVie's Total Revenue, 2013-2018

AbbVie's Monoclonal Antibody Revenue (by Product), 2013-2018

Amgen's Products Being Developed by Jun. 2019

Revenue of Amgen's Monoclonal Antibody Products Sold, 2009-2018

Revenue of Amgen ENBREL (by Region), 2009-2018

ENBEL's Patent Term

Similar Competitive Products of ENBEL

Revenue of Amgen Panitumumab (by Region), 2009-2018

Panitumumab's Patent Term

Revenue of Amgen Denosumab (by Region), 2010-2018

Denosumab's Patent Term

Similar Competitive Products of Denosumab

Erenumab-aooe's Patent Term

Similar Competitive Products of Erenumab-aooe

Revenue Breakdown of Amgen Blinatumomab (by Region), 2015-2018

Blinatumomab's Patent Term

Revenue Breakdown of Amgen Evolocumab (by Region), 2014-2018

Evolocumab's Patent Term

Revenue and Net Income of Chengdu Taihe Health Technology, 2014-2018

Revenue and Net Income of Chengdu Huasun Biotech, 2013-2018

Key Partners of Zhejiang Hisun Pharmaceutical

Revenue and Net Income of Zhejiang Hisun Pharmaceutical, 2012-2018

R&D Costs and % of Total Revenue of Zhejiang Hisun Pharmaceutical, 2013-2018

R&D Costs of Some Projects and % of Total Revenue of Zhejiang Hisun Pharmaceutical, 2017

Monoclonal Antibody R&D Progress of Zhejiang Hisun Pharmaceutical, by H1 2018

Business Territory of Yunnan Walvax Biotechnology

Revenue and Net Income of Yunnan Walvax Biotechnology, 2012-2018

R&D Costs and % of Total Revenue of Yunnan Walvax Biotechnology, 2013-2018

Progress of Yunnan Walvax Biotechnologys' Major Fundraising Projects, by H1 2018

Product Registration and Application of Yunnan Walvax Biotechnology, by H1 2018

Monoclonal Antibody R&D Progress of Genor Biopharma, by H1 2018

Revenue and Net Income of Shanghai Fosun Pharmaceutical, 2013-2018

R&D Costs and % of Total Revenue of Shanghai Fosun Pharmaceutical, 2013-2018

Monoclonal Antibody R&D Progress of Henlius, by the end of 2018

Rituximab Similimum R&D History of Henlius

Total Revenue, Net Income and R&D Investment of Henlius, 2016-2018

Revenue and Net Income of Beijing SL Pharmaceutical, 2012-2018

Revenue and Net Income of Huahai Pharmaceutical, 2012-2018

Monoclonal Antibody Products Being Developed and Progress of Huahai Pharmaceutical, by the end of 2017

Revenue and Net Income of Livzon Pharmaceutical Group, 2012-2018

R&D Costs and % of Total Revenue of Livzon Pharmaceutical Group, 2013-2018

Purposes of Funds Raised by Non-public Offering of Livzon Pharmaceutical Group, 2016

Monoclonal Antibody R&D Progress of Livzon Pharmaceutical Group, by the end of 2018

Monoclonal Antibody Drugs Being Developed and Progress of Mabpharm, by March 2019

Revenue and Net Income of Hualan Biological Engineering, 2013-2018

R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2018

Revenue and Net Income of Hualan Genetic Engineering, 2015-2018

Revenue and Net Income of Anhui Anke Biotechnology, 2012-2018

Monoclonal Antibody R&D Progress of Anhui Anke Biotechnology, by March 2019

Purposes of Funds Raised by Non-public Offering of Anhui Anke Biotechnology, 2018

Revenue and Net Income of Innovent Biologics, 2017-2018

Main Product Development of Innovent Biologics, by the end of 2018

Revenue and Net Income of Shanghai Junshi Biosciences, 2016-2018

Monoclonal Antibody R&D Progress of Shanghai Junshi Biosciences, 2018

Global Layout of Shanghai Junshi Biosciences

Toripalimab of Shanghai Junshi Biosciences

Revenue and Net Income of Hengrui Medicine, 2015-2018

Revenue Structure of Hengrui Medicine (by Product), 2017-2018

Monoclonal Antibody R&D of Hengrui Medicine, 2018

Revenue and Net Income of Changchun High and New Technology Industries (Group), 2015-2018

Revenue of Changchun High and New Technology Industries (Group) (by Product), 2017-2018

GenSci's Operation, 2017-2018

Operation of Changchun BCHT Biotechnology, 2017-2018

Technical Roadmap of Trinomab Natural Human Monoclonal Antibody

Revenue and Net Income of Guilin Sanjin Pharmaceutical, 2015-2018

Operation of Dragonboat Biopharmaceutical, 2017-2018

Revenue and Net Income of 3SBio Group, 2015-2018

Monoclonal Antibody R&D Progress of 3SBio Group, by the end of 2017

目次

Global monoclonal antibody market can be presented as follows:

1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.

Monoclonal antibody drugs have been maturing from a research target to an improved technology, from clinical research to commercialization over the past three decades. In recent years, the number of monoclonal antibody drugs approved for launch proliferated, with 78 approved and available on the market as of May 2018.

In 2017, 7 of 10 best-selling drugs worldwide were monoclonal antibody drugs, the fastest growing segment in global bio-pharmaceutical market. In Merck's case, the sales of its Keytruda which was launched in 2014, hit RMB7.171 billion in 2018 alone.

Global monoclonal antibody market has been expanding over the recent years, with its size posting USD115.2 billion in 2018, a year-on-year increase of 11%. As of April 2019, there have been 182 monoclonal antibody drugs undergoing Phase III clinical trials worldwide. It is expected that many a monoclonal antibody drug will be approved and rolled out into the market in the forthcoming years, favoring a ballooning market size to USD240.2 billion in 2025.

The world's monoclonal antibody market is now almost carved up by Roche, Johnson & Johnson, Merck, Novartis, AbbVie and Amgen. In 2018, the global top eight monoclonal antibody drugs by sales, collectively USD64,052 million, were HuMiRA, Herceptin, Avastin, Keytruda, Rituxan, Remicade, Stelara and ENBREL?, with a combined 55.6% share in global market.

2. The Chinese monoclonal antibody market has a rosy prospect but players compete with each other fiercely.

As of April 2019, the National Medical Products Administration (NMPA) of China has approved the roll-out of 33 antibody drugs (including fusion protein), including 21 imported and 12 homemade products, far lower than the volume approved by the US Food and Drug Administration (FDA). China has quickened its pace of approving monoclonal antibody drugs led by Opdivo and Keytruda, and projects to list them into its medical insurance drugs catalogue, giving impetus to the expansion of the market in the country.

China's monoclonal antibody market developed by leaps and bounds between 2013 and 2017 at a CAGR of 15.6%, and would be worth RMB14.2 billion in 2018, 20.3% higher than in the previous year. The monoclonal antibody market size in China will grow up to RMB120.7 billion in 2025 as more new such drugs and biosimilar drugs are approved and launched.

In China, most monoclonal antibody drugs are at the clinical research stage, the majority of which are biosimilar products. Among those on the market, Sintilimab from Innovent Biologics and Toripalimab from Shanghai Junshi Biosciences are two new monoclonal antibody drugs, and HLX01 developed by Shanghai Henlius Biotech is China's first biosmilar. Other monoclonal antibody developers include Biotech Pharma, Chengdu Taihe Health Technology Group, Zhejiang Hisun Pharmaceutical, Genor Biopharma, Beijing Shuanglu Pharmaceutical, Zhejiang Huahai Pharmaceutical, Livzon Pharmaceutical Group, Mabpharm, Hualan Biological Engineering and Anhui Anke Biotechnology (Group) Co., Ltd..

Companies like Innovent Biologics, Shanghai Junshi Biosciences and Shanghai Henlius Biotech that stay ahead of others in drug approval for launch, will have an edge over their peers in the market. But several players' application for production and Phase III clinical trials by a number of companies which will then release their products under approval, means that competition between local firms and their foreign counterparts, between reference listed drugs (RLD) and biosimilars, will remain tough in the Chinese monoclonal antibody market.

3. As star monoclonal antibody drug patents expire, generic drugs will shock the market.

In the next five years, as the duration of star monoclonal antibody drug patents draws to an end, biosimilar market will be the battlefield of numerous pharmaceutical companies. Generic drugs for four monoclonal antibody drugs have been approved and become available on the market in European Union and the United States, signaling their squeeze of RLD in the market.

4. Monoclonal antibodies with PD-1 and PD-L1 as targets spring up.

The editorial board of the New England Journal of Medicine indicates that the PD-1 monoclonal antibody is the best anticancer performer over the past thirty years. Following the approval and release of Opdiva and Keytruda, two PD-1 targeted monoclonal antibodies in 2014, PD-1/PD-L1 monoclonal antibody drugs like Tecentriq, Bavencio, Imfinzi and Libtayo have also been brought to market.

Sales of Opdivo and Keytruda have been on the rise since their launch, especially the later with sales of USD7,171 million in 2018, nearly doubling the figure in the previous year. Global PD-1/PD-L1 monoclonal antibody market size reached as much as USD13.9 billion in 2018, and will expectedly surge to a staggering USD57.4 billion in 2025.

The report highlights the following:

Global monoclonal antibody industry (status quo, market size, market structure, competitive landscape and development prospects);

China's monoclonal antibody industry (status quo, market size, market segments, competitive pattern and development outlook);

Six foreign and nineteen Chinese monoclonal antibody companies (profile, operation and monoclonal antibody business).

Table of Contents

1. Overview of Monoclonal Antibody Industry

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 Technological Development

2. Overview of Global Monoclonal Antibody Industry

  • 2.1 Status Quo
  • 2.2 Market Size
  • 2.3 Market Structure
  • 2.4 Competition Pattern
  • 2.5 Development Prospect and Prediction
    • 2.5.1 New Monoclonal Antibody Drugs Will Be Approved and Available on the Market Successively
    • 2.5.2 Patents for Star Monoclonal Antibody Drugs Expire and Generic Drugs Hit the Market
    • 2.5.3 Monoclonal Antibody Taking PD-1 and PD-L1 as the Targets Is a Rising Star

3. Chinese Monoclonal Antibody Market

  • 3.1 Status Quo
  • 3.2 Market Size
  • 3.3 Market Segments
    • 3.3.1 Rituximab (Mabthera)
    • 3.3.2 Bevacizumab (Avastin)
    • 3.3.3 Trastuzumab (Herceptin)
    • 3.3.4 Adalimumab (Humira)
    • 3.3.5 Omalizumab
    • 3.3.6 Cetuximab
    • 3.3.7 Infliximab
  • 3.4 Competition Pattern
  • 3.5 Development Prospect
    • 3.5.1 Good Prospects of Monoclonal Antibody Market
    • 3.5.2 Rapid Expansion of PD-1 & PD-L1 Market
    • 3.5.3 Vigorous Development of Monoclonal Antibody Biosimilar Drug Market

4. Key Foreign Monoclonal Antibody Agent Enterprises

  • 4.1 Roche Pharmaceuticals
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 R&D and Investment
    • 4.1.5 Monoclonal Antibody Business(Genentech)
    • 4.1.6 Business in China
  • 4.2 Johnson & Johnson
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 R&D and Investment
    • 4.2.5 Monoclonal Antibody Business
    • 4.2.6 Business in China
  • 4.3 Merck & Co Inc.
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 R&D and Investment
    • 4.3.5 Monoclonal Antibody Business
    • 4.3.6 Business in China
  • 4.4 Novartis
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 R&D and Investment
    • 4.4.5 Monoclonal Antibody Business
    • 4.4.6 Business in China
  • 4.5 AbbVie
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 R&D and Investment
    • 4.5.5 Monoclonal Antibody Business
    • 4.5.6 Business in China
  • 4.6 Amgen
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 R&D and Investment
    • 4.6.5 Monoclonal Antibody Business
    • 4.6.6 Business in China

5. Key Chinese Monoclonal Antibody Agent Enterprises

  • 5.1 BIOTECH Pharmaceutical Co., Ltd.
    • 5.1.1 Profile
    • 5.1.2 R&D and Production
    • 5.1.3 Monoclonal Antibody Business
  • 5.2 Chengdu Taihe Health Technology Group Inc.,Ltd.
    • 5.2.1 Profile
    • 5.2.2 Operation
    • 5.2.3 Monoclonal Antibody Business
  • 5.3 Shanghai Medipharm Biotech Co.,Ltd.
    • 5.3.1 Profile
    • 5.3.2 Monoclonal Antibody Business
  • 5.4 Zhejiang Hisun Pharmaceutical Co., Ltd.
    • 5.4.1 Profile
    • 5.4.2 Operation
    • 5.4.3 R&D
    • 5.4.4 Monoclonal Antibody Business
  • 5.5 Yunnan Walvax Biotechnology Co, Ltd.
    • 5.5.1 Profile
    • 5.5.2 Operation
    • 5.5.3 R & D
    • 5.5.4 Monoclonal Antibody Business
  • 5.6 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    • 5.6.1 Profile
    • 5.6.2 Operation
    • 5.6.3 R & D and Investment
    • 5.6.4 Monoclonal Antibody Business
  • 5.7 Beijing SL Pharmaceutical Co., Ltd.
    • 5.7.1 Profile
    • 5.7.2 Operation
    • 5.7.3 Monoclonal Antibody Business
  • 5.8 Zhejiang Huahai Pharmaceutical Co.,Ltd.
    • 5.8.1 Profile
    • 5.8.2 Operation
    • 5.8.3 Monoclonal Antibody Business
  • 5.9 Livzon Pharmaceutical Group Inc.
    • 5.9.1 Profile
    • 5.9.2 Operation
    • 5.9.3 R & D
    • 5.9.4 Monoclonal Antibody Business
  • 5.10 Mabpharm Limited
    • 5.10.1 Profile
    • 5.10.2 Monoclonal Antibody Business
  • 5.11 Hualan Biological Engineering Inc.
    • 5.11.1 Profile
    • 5.11.2 Operation
    • 5.11.3 R & D
    • 5.11.4 Monoclonal Antibody Business
  • 5.12 Anhui Anke Biotechnology (Group) Co., Ltd.
    • 5.12.1 Profile
    • 5.12.2 Operation
    • 5.12.3 Monoclonal Antibody Business
  • 5.13 Innovent Biologics, Inc.
    • 5.13.1 Profile
    • 5.13.2 Operation
    • 5.13.3 Monoclonal Antibody Business
  • 5.14 Shanghai Junshi Biosciences Co., Ltd.
    • 5.14.1 Profile
    • 5.14.2 Operation
    • 5.14.3 Monoclonal Antibody Business
  • 5.15 Hengrui Medicine Co., Ltd.
    • 5.15.1 Profile
    • 5.15.2 Operation
    • 5.15.3 Monoclonal Antibody Business
  • 5.16 Changchun High and New Technology Industries (Group) Inc.
    • 5.16.1 Profile
    • 5.16.2 Operation
    • 5.16.3 Monoclonal Antibody Business
  • 5.17 Guilin Sanjin Pharmaceutical Co., Ltd.
    • 5.17.1 Profile
    • 5.17.2 Operation
    • 5.17.3 Monoclonal Antibody Business
  • 5.18 Shenzhen Main Luck Pharmaceuticals Inc.
    • 5.18.1 Profile
    • 5.18.2 Monoclonal Antibody Business
  • 5.19 3SBio Group
    • 5.19.1 Profile
    • 5.19.2 Operation
    • 5.19.3 Monoclonal Antibody Business
Back to Top